Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer

BACKGROUND: Canfosfamide is a novel glutathione analog activated by glutathione S-transferase P1-1. This study evaluated the safety and efficacy of canfosfamide in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum resistant ovarian cancer. Patients with platinum resist...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kavanagh, John J, Levenback, Charles F, Ramirez, Pedro T, Wolf, Judith L, Moore, Carla L, Jones, Marsha R, Meng, Lisa, Brown, Gail L, Bast, Robert C
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2010
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2851575/
https://ncbi.nlm.nih.gov/pubmed/20222977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-3-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados